MTOR and fatty liver disease: In addition, AMPK can inhibit the downstream targets such as sterol regulatory element-binding protein-1c (SREBP-1c) and rapamycin target (mTOR), reduce lipid synthesis, promote autophagy and β-oxidation, and reduce hepatic steatosis in MAFLD (Figures 3A,B).